Étang-sur-Arroux, France
Étang-sur-Arroux, France

Time filter

Source Type

Teichert N.,ARDA | Teichert N.,French National Institute for Agricultural Research | Teichert N.,University of Pau and Pays de l'Adour | Richarson M.,ARDA | And 3 more authors.
Aquatic Biology | Year: 2012

Among amphidromous species, life-history traits of pelagic larvae show high variability between and within species and populations, due to the spatial and temporal variability of the marine environment. Temperature, food availability and seasonal conditions affect survival and larval growth. Among species with an extensive reproduction period, the pelagic conditions encountered by larvae vary according to the hatching date and induce variability in the postlarval and recruitment traits. Post-larvae of the amphidromous goby Cotylopus acutipinnis were collected every new moon between February 2008 and December 2009 at the mouth of a river on Reunion (Mascarene Archipelago, SW Indian Ocean). The relationship between pelagic larval duration (PLD), growth and marine temperature conditions was analysed using the chronological properties of otoliths. C. acutipinnis PLD (mean ± CI: 108.2 ± 1.2 d; range: 66 to 164 d) and size-atrecruitment (mean ± CI: 20.5 ± 0.1 mm; range: 17 to 23 mm) varied widely depending on the time of year. Back-calculation of hatching dates showed an extensive spawning season between November and July, which included 2 spawning peaks during the early austral summer and early winter. Summer spawning and high seawater temperature induced faster growth, shorter PLDs and smaller size-at-recruitment compared to early winter reproduction. The significant morphological changes that were demonstrated among amphidromous recruits might influence postrecruitment survival and juvenile settlement in freshwater. Selective mortality may occur according to early life-history traits such as growth patterns, size-at-recruitment and post-larval condition, and should be considered in population management. © Inter-Research 2012.


News Article | December 22, 2016
Site: www.businesswire.com

BOSTON, Mass., IRVINE, Calif., & REHOVOT, Israel--(BUSINESS WIRE)--Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), today announced that the two companies, together with the shareholders of Otic Pharma, have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai. The transaction will result in a NASDAQ-listed company focused on the development and commercialization of products for ENT disorders, including Otic Pharma’s lead candidate which is a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. The company will operate under the name OticPharma, Inc., and will be led by Gregory J. Flesher, current Chief Executive Office of Otic Pharma Ltd. Current President and Chief Executive Officer of Tokai, Jodie Morrison, will remain as a member of the board of directors. “Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing value for our shareholders over the long-term,” said Jodie Morrison, President and CEO of Tokai Pharmaceuticals. “We believe the proposed transaction with Otic Pharma, a company that has both a promising pipeline and an experienced leadership team with a track record of creating significant shareholder value in public pharmaceutical companies, advances this goal.” “Our lead program in otitis media, OP-02, has significant potential,” said Gregory J. Flesher, Chief Executive Officer of Otic Pharma. “OP-02 is an investigational drug product designed to break the cycle of recurrent and chronic otitis media which affect millions of people around the world. We expect to have phase 1 clinical pharmacodynamic data in the first half of 2017 and, with this transaction, to have the capital needed to be able to move directly into phase 2 development to explore the product’s ability to prevent otitis media in children.” Under the terms of the agreement, the shareholders of Otic Pharma will receive a total of 32,172,209 shares of newly issued Tokai common stock, while outstanding Otic Pharma options and convertible securities will be assumed by Tokai. Upon the exchange, it is expected that existing Tokai stockholders will own approximately 40% of the combined company, with existing Otic Pharma shareholders owning approximately 60%. The transaction has been unanimously approved by the boards of directors of both companies and shareholders of Otic Pharma. Tokai’s largest stockholder, Apple Tree Partners, who holds approximately 35% of Tokai’s common stock has entered into an agreement in support of the proposed transaction. The transaction is expected to close during the first quarter of 2017, subject to customary closing conditions, including approval by shareholders of Tokai. Wedbush PacGrow advised Tokai Pharmaceuticals and Piper Jaffray & Co. advised Otic Pharma in the proposed transaction. Wilmer Cutler Pickering Hale and Dorr LLP and Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. served as legal counsel to Tokai and Gibson, Dunn & Crutcher LLP and Yigal Arnon & Co. served as legal counsel to Otic Pharma. Upon the close of the proposed transaction, the board of directors of the combined company will consist of seven members, three to be designated by Tokai and four to be designated by Otic Pharma. Officers of the new company will be Gregory J. Flesher, President and Chief Executive Officer; Christine G. Ocampo, Chief Financial and Compliance Officer; and Dr. Catherine C. Turkel, Chief Development Officer. An Otic Pharma investor syndicate, including current shareholders and members of the management team, has committed to invest $7 million of additional capital in connection with the share purchase agreement. Tokai and Otic Pharma will host a conference call in early January to discuss the proposed transaction. Call in information will be provided in a future press release. Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com. Tokai Pharmaceuticals is a biopharmaceutical company previously focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The ARMOR2 and ARMOR3-SV clinical trials of Tokai’s drug candidate, galeterone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been closed, with only patients in ARMOR2 long-term extension continuing treatment at this time. Plans remain in effect to present data from the ARMOR3-SV trial in a scientific forum once fully available and analyzed. Assessment of plans for galeterone, the ARDA platform and Tokai’s AR-V7 assay work are underway at this time. Additional Information about the Proposed Transaction and Where to Find It In connection with the proposed transaction, Tokai intends to file with the Securities and Exchange Commission (the “SEC”) a proxy statement in connection with the proposed transaction with Otic Pharma and furnish or file other materials with the SEC in connection with the proposed transaction. The definitive proxy statement will be sent or given to the stockholders of Tokai and will contain important information about the proposed transaction and related matters. BEFORE MAKING ANY VOTING DECISION, TOKAI’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THOSE OTHER MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. The proxy statement and other relevant materials (when they become available), and any other documents filed by Tokai with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, security holders will be able to obtain free copies of the proxy statement upon request directed to the Corporate Secretary at 255 State Street, Boston MA 02109, or by phone at 617-225-4305. Tokai, Otic Pharma and each of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Tokai in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction described herein will be included in the proxy statement described above. Additional information regarding the directors and executive officers of Tokai is included in proxy statement for its 2016 Annual Meeting, which was filed with the SEC on April 29, 2016, and is supplemented by other public filings made, and to be made, with the SEC by Tokai. Any statements in this press release that are not historical facts, including statements regarding the structure, timing and completion of the proposed transaction; Tokai’s continued listing on NASDAQ prior to and after the proposed transaction; expectations regarding the capitalization, cash balances and working capital, resources and ownership structure of the company after the transaction; expectations regarding the sufficiency of the company’s resources to fund the advancement of any development program or the completion of any clinical trial; the nature, strategy and focus of the company after the transaction; the safety, efficacy and projected development timeline and commercial potential of any product candidates; the expectations regarding voting by Tokai stockholders: and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties associated with stockholder approval of and the ability to consummate the proposed transaction; whether the anticipated cash resources will be sufficient to fund operations for the period anticipated and to conduct the anticipated studies; whether the necessary approvals to commence clinical trials of Otic’s product candidates can be obtained on a timely basis or at all; and whether the results of clinical trials will warrant submission for regulatory approval, any such submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies and, if any of such product candidates obtains such approval, it will be successfully distributed and marketed. Risks and uncertainties facing Tokai are discussed in the “Risk Factors” section of its quarterly report on Form 10-Q for the three months ended September 30, 2016 Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the companies expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


News Article | February 15, 2017
Site: www.PR.com

Up for 10 Awards from the American Resort Development Association “Brand Tango is honored to be recognized in so many categories, from brochures to technology applications to immersive websites,” says James Kluetz, president and chief creative officer. “As the industry evolves to meet the needs of today’s consumers, we’ve expanded our capabilities to provide more digital branding and technology services. It’s a thrill to be a part of it.” The awards will be presented on March 29 at the 2017 ARDA World convention held by the American Resort Development Association at the Hyatt Regency in New Orleans. Brand Tango is the place where ideas, technology and brand expression are thoughtfully blended and served up daily. Brand Tango’s client list spans a wide range of industries including hospitality, vacation ownership, food and beverage, consumer products, financial services, and medical. Relying on their decades of combined expertise, the agency’s principals and staff help clients find solutions that deliver measurable results. Visit brandtango.com to learn more. Deerfield Beach, FL, February 14, 2017 --( PR.com )-- Brand Tango, an award-winning branding, design and digital agency located in South Florida, has had nine Advertising and Promotion entries selected as finalists in the American Resort Development Association’s 2017 ARDY awards competition. In addition, the Brand Tango creative team is also a finalist for an ARDY in the Graphic Design Professional or Team category. Up for top honors is work for Brand Tango clients VIA Destination Club, Grupo Questro’s Ritz-Carlton Reserve Residences, Sunset World, Unlimited Vacation Club by AMResorts, DAE, and Magic Development, along with Brand Tango’s own website.“Brand Tango is honored to be recognized in so many categories, from brochures to technology applications to immersive websites,” says James Kluetz, president and chief creative officer. “As the industry evolves to meet the needs of today’s consumers, we’ve expanded our capabilities to provide more digital branding and technology services. It’s a thrill to be a part of it.”The awards will be presented on March 29 at the 2017 ARDA World convention held by the American Resort Development Association at the Hyatt Regency in New Orleans.Brand Tango is the place where ideas, technology and brand expression are thoughtfully blended and served up daily. Brand Tango’s client list spans a wide range of industries including hospitality, vacation ownership, food and beverage, consumer products, financial services, and medical. Relying on their decades of combined expertise, the agency’s principals and staff help clients find solutions that deliver measurable results. Visit brandtango.com to learn more. Click here to view the list of recent Press Releases from Brand Tango


Ellien C.,University Pierre and Marie Curie | Valade P.,Center Regional dApplication Aquacole | Bosmans J.,ARDA | Taillebois L.,British Petroleum | And 2 more authors.
Cybium | Year: 2011

The widely distributed amphidromous goby Sicyopterus lagocephalus needs drastic change of habitat to fulfil its life-cycle: adults live and spawn in rivers, where eggs hatch in pro-larvae that have to reach the sea in a narrow temporal scale, to acquire marine characteristics, and begin their oceanic dispersal as planktonic larvae. Post-larvae return to rivers where they recruit and grow to the adult reproductive stage. Such a life-cycle raises the question of salinity changes between these different developmental stages. Through an experimental approach, we observed and described the chronology in the appearance of marine larvae characteristics, according to 5 different salinities ranging, from 0% to 100% seawater. It appears that 5. lagocephalus needs an increase of salinity to acquire marine morphological characteristics, without being strict upon the salinity value itself. Whatever the tested salinity, the transformation of freshwater pro-larvae into marine larvae follows the same pattern within 48h: the yolk sac is absorbed until it only consists in the oil globule, pectoral fins develop and become functional, pigmentation spreads above the digestive tract, eyes become pigmented and functional, mouth and anus open, and the head appears more shaped. Pro-larvae behaviour evolves once in seawater: larvae remain on vertical position with their head oriented downwards (i.e., freshwater pro-larval behaviour) but they also spend more time horizontally, after the opening of the mouth, showing a behaviour of horizontal swimming, with acceleration phases, that may be interpreted as a hunting behaviour. Even a low salinity (i.e., less than 10% of seawater) is sufficient to induce these transformations, with the same timing than 100% seawater, leading to the conclusion that we did not underline a minimum salinity threshold for the acquisition of marine larvae morphological characteristics. Moreover, if the pro-larvae, after a first contact with brackish water, secondarily return to freshwater, their transformation is not stopped. However, pro-larvae that remain in 100% freshwater do not develop into marine larvae, neither in their morphological characteristics nor in their behaviour, and they die within 4 days.


Barrut B.,ARDA | Blancheton J.-P.,French Research Institute for Exploitation of the Sea | Champagne J.-Y.,École Centrale Lyon | Grasmick A.,Montpellier University
Aquacultural Engineering | Year: 2012

A study was undertaken to measure the water flow (Q w) delivered by a vacuum airlift designed for recirculating aquaculture systems (RAS) in fresh (<1‰ of salinity) and sea water (35‰ of salinity). The vacuum airlift consists of two concentric tubes connected at their top to a depression chamber. The water rises in the inner tube as a result of air being injected in its lower section and flows back through the external downcomer tube. The vacuum airlift was adjusted at three different lengths: 2, 4 or 6m and water discharge could be lifted from 0 to 30cm. Air flow rate (Q g) varied from 0 to 80Lmin -1. Different types of air injectors were tested, delivering different bubble sizes (0.1-5mm) depending on porosity and functioning at low or high injection pressure. Results show an increase in water flow when pipe length and air flow were increased and lift height reduced. Water flow also depended on the type of water and ranged from 0 to 35 m 3h -1 (0-580Lmin -1) for fresh water and only from 0 to 20 m 3h -1 (0-330Lmin -1) for sea water (for a 6m high vacuum airlift). This difference was attributed to the smaller bubble diameter and higher gas holdup (e{open} g) observed in sea water (0-20%) compared to fresh water (0-10%). When bubbles were present in the downcomer tube, they created a resistance to flow (counter-current airlift) that slowed down liquid velocity and thus water flow. Increasing the vacuum made it possible to use low air injection pressures and high injection depths. Vacuum also increased bubble size and airflow (20Lmin -1 at atmospheric pressure to 60Lmin -1 at 0.3barA) and thus water flow rates. With RAS, the presence of fish feed in water rapidly increased water flow delivered by the airlift because of changes of water quality and gas holdup. When working with low head RAS (under 0.3m), vacuum airlift could save up to 50% of the energy required for centrifugal pumps. An empirical predictive model was developed and calibrated. Simulation shows a good correlation between predicted values and measurements (R 2=0.96). © 2011 Elsevier B.V.


Barrut B.,ARDA | Blancheton J.-P.,French Research Institute for Exploitation of the Sea | Champagne J.-Y.,École Centrale Lyon | Grasmick A.,Montpellier University
Aquacultural Engineering | Year: 2012

In aquaculture, oxygen transfer and carbon dioxide stripping are the first limiting factors to fish rearing intensification. In this study we measured the O 2 and CO 2 mass transfer coefficient (K La) for a vacuum airlift in fresh (<1‰ salinity) and sea water (35‰ salinity) recirculating aquaculture systems (RAS). The airlift was composed of two concentric tubes: an inner riser tube and an external downcomer tube and can be adjusted at three different heights: 2, 4 or 6m. Several types of air injectors were tested, delivering different sizes of bubble swarms depending on their porosity and functioning conditions (low or high injection pressure), with air flows varying from 0 to 80Lmin -1. Experiments were also carried out at different water circulation velocities and with cold (7°C) and warm water (22°C). The best transfer coefficient (K La) value was obtained at a high air flow rate, a high temperature and with reduced bubble size. Results showed that K La was not affected by water salinity, but it was slightly affected by water flow (Q w), airlift inner pipe length and vacuum. The presence of vacuum reduces gas solubility in water and facilitates CO 2 stripping. The comparison between O 2 and CO 2 transfers showed that higher K La values were obtained for O 2 than for CO 2 in fresh and sea water, probably due to chemical reactions between the CO 2 and water. For RAS, the vacuum airlift provides a Standard Aeration Efficiency (SAE) of 1.13kgO 2kWh -1 and a Standard Stripping Efficiency (SSE) of 1.8kgO 2kWh -1 or 0.023kgCO 2kWh -1. In rearing water, CO 2 and O 2 transfers were negatively affected when feed was added. An empirical model for CO 2 mass transfer coefficient prediction was developed and calibrated. Simulation shows a good correlation between predicted and measured values (R 2=0.87). © 2011 Elsevier B.V.


Barrut B.,ARDA | Blancheton J.-P.,French Research Institute for Exploitation of the Sea | Muller-Feuga A.,Microphyt | Rene F.,French Research Institute for Exploitation of the Sea | And 4 more authors.
Bioresource Technology | Year: 2013

Low-energy and low-cost separation of microalgae from water is important to the economics of microalgae harvesting and processing. Flotation under vacuum using a vacuum gas lift for microalgae harvesting was investigated for different airflow rates, bubble sizes, salinities and harvest volumes. Harvesting efficiency (HE) and concentration factor (CF) of the vacuum gas lift increased by around 50% when the airflow rate was reduced from 20 to 10Lmin-1. Reduced bubble size multiplied HE and CF 10times when specific microbubble diffusers were used or when the salinity of the water was increased from 0‰ to 40‰. The reduction in harvest volume from 100 to 1L increased the CF from 10 to 130. An optimized vacuum gas lift could allow partial microalgae harvesting using less than 0.2kWhkg-1DW, thus reducing energy costs 10-100 times compared to complete harvesting processes, albeit at the expense of a less concentrated biomass harvest. © 2012 Elsevier Ltd.


Barrut B.,ARDA | Blancheton J.-P.,French Research Institute for Exploitation of the Sea | Callier M.,French Research Institute for Exploitation of the Sea | Champagne J.-Y.,École Centrale Lyon | Grasmick A.,Montpellier University
Aquacultural Engineering | Year: 2013

The accumulation of particulate organic matter (POM) in recirculating aquaculture systems (RAS) has become an important issue with the intensification of finfish production. The objective of this study was to assess the foam fractionation efficiency of a vacuum airlift in different conditions (POM concentrations, airflow rates, bubble sizes, water renewal rates and feed addition). In sea water, the vacuum airlift allowed removing 20% of the initial POM concentration per hour (foam fractionation efficiency), corresponding to a 20.7-fold concentration factor between the tank and the foam. In rearing conditions, efficiency increased with decreasing water renewal rate or increasing POM concentration. An increase in airflow rate from 10 to 80Lmin-1 in the vacuum airlift significantly decreased foam fractionation efficiency when feed was added to the water. The impact of feeding was only observed with high airflow rates where bubble coalescence occurred. Calculated POM production by fish ranged between 15.9 and 23.5gh-1 and was equivalent to estimations based on feed conversion ratio (FCR). This indicated that all the POM produced was extracted by the vacuum airlift. © 2012 Elsevier B.V..


PubMed | ARDA, Plateforme Technologique Of Resonance Magnetique Nucleaire Et Of Resonance Paramagnetique Electronique Of Luniversite Of Bretagne Occidentale, University of Southern Brittany and University of French Polynesia
Type: | Journal: Talanta | Year: 2016

In this study, we report the chemical characterization of 47 tropical microalgae and cyanobacteria by HR-MAS. The generated data confirm the interest of HR-MAS as a rapid screening technique with the major advantage of its easiness. The sample is used as powder of freeze-dried microalgae without any extraction process before acquisition. The spectral fingerprints of strains are then tested as variables for a chemotaxonomy study to discriminate cyanobacteria and dinoflagellates. The individual factor map generated by PCA analysis succeeds in separating the two groups, essentially thanks to the presence of specific carbohydrates. Furthermore, more resolved signals enable to identify many osmolytes. More precisely the characteristics of 2-O-alpha-D-glucosylglycerol (GG) are observed in all 21 h-MAS spectra of tropical cyanobacteria. After specific extraction, complementary analysis by 1D and 2D-NMR spectroscopies validates the identification of this osmolyte.


Taillebois L.,French Natural History Museum | Keith P.,French Natural History Museum | Valade P.,ARDA | Torres P.,French Natural History Museum | And 3 more authors.
General and Comparative Endocrinology | Year: 2011

After oceanic migration, post-larvae of the amphidromous Sicyopterus lagocephalus recruit to rivers in Reunion Island. As they enter the river mouth, post-larvae undergo many morphological, physiological and behavioural changes. These drastic changes, which allow them to change feeding regime and to colonise the juvenile and adult freshwater habitat, are defined as metamorphosis. The endocrine control of these changes has never been investigated in Gobioid fish. Here, we investigated whether thyroid hormones (TH) influence metamorphosis in recruiting S.lagocephalus. An analytical study was first performed on a cohort of 2400 fish caught at post-larval stage 1 and maintained for 37days after capture in a flume tank (fluvarium), which replicates as closely as possible the natural conditions. Biometrical parameters (total and standard lengths, corner of mouth angle, body mass and condition factor) and whole-body thyroxine (T 4) and triiodothyronine (T 3) contents were measured on fish, sampled at regular intervals during these 37days (192 fish). TH levels, measured by radioimmunoassays, were highest when morphological changes, such as the change in the position of the mouth, were most important. An experimental approach was then used to test the effect of the hormonal treatment (T 4 or thiourea, TU, a TH inhibitor) on biometrical parameters of 576 post-larvae. The change in the position of the mouth was significantly accelerated in the T 4-treated post-larvae, while it was significantly delayed in the TU-treated post-larvae, compared to controls. Our study suggests that S.lagocephalus post-larva undergoes a true metamorphic event under the control of thyroid hormones at the time of its recruitment into the river. © 2011 Elsevier Inc.

Loading ARDA collaborators
Loading ARDA collaborators